DUBLIN–(BUSINESS WIRE)–The “Systemic Lupus Erythematosus (SLE) – Market Insights, Epidemiology, and Market Forecast – 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Systemic Lupus Erythematosus (SLE) – Market Insights, Epidemiology, and Market Forecast-2028′ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Systemic Lupus Erythematosus from 2017 to 2028 segmented by seven major markets.
The phenomenon of Systemic Lupus Erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy
According to the American College of Rheumatology, Systemic lupus erythematosus, is referred to as chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain’.
Systemic Lupus Erythematosus – Disease Understanding and Treatment Algorithm
SLE is a disease of unknown etiology with a variety of presenting features and manifestations. The majority of the pathology in SLE is related to deposits of immune complexes in various organs, which triggers complement other mediators of inflammation. Symptoms vary from person to person, depending on what part of the body is affected, can be mild, moderate, or severe. Clinical manifestations are heterogeneous, vary as a result of the type of the disease and organ involvement of an individual. Diagnosis can be difficult because lupus mimics many other diseases; it requires clinical and serologic criteria.
Systemic Lupus Erythematosus Epidemiology
The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Severity Specific Prevalence) scenario of Systemic Lupus Erythematosus in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to this research, the total Diagnosed Prevalent cases of Systemic Lupus Erythematosus (SLE) in the 7MM was found to be 484,213 in 2017. The prevalence of Systemic Lupus Erythematosus in the 7MM is expected to increase during the study period of 2017-2028.
Systemic Lupus Erythematosus Drug Chapters
This segment of the Systemic Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of SLE in the US is mainly accounted for the management options consisting of Corticosteroids, Immunosuppressants, Antimalarials (Plaquenil) and Biologics (Rituximab, Belimumab). Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used to treat inflammation and pain.
Hydroxychloroquine (Plaquenil) and Belimumab (Benlysta) are approved therapies for the treatment of SLE in the US.
Detailed chapters of current therapies, such as Belimumab (GlaxoSmithKline) and emerging therapies, such as Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Ustekinumab (Janssen Pharmaceutical), Atacicept (Merck), Dapirolizumab pegol (UCB Pharma/ Biogen), CC-220 (Celgene), IFNa KINOID (Neovacs), ILT-101 (Iltoo Pharma), BIIB059 (Biogen), Lulizumab (Bristol-MyersSquibb), Obexelimab (Xencor), KZR-616 (Kezar Life Sciences), Cenerimod (Idorsia Pharmaceuticals) and others have also been provided in the report.
Systemic Lupus Erythematosus Market Outlook
The Systemic Lupus Erythematosus market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to this research, the market for Systemic Lupus Erythematosus in 7MM was found to be approximately USD 1,447.35 million in 2017.
Systemic Lupus Erythematosus market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Systemic Lupus Erythematosus treatment market in the US is expected to dominate the market during the forecast period (2019-2028).
Systemic Lupus Erythematosus Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, Belimumab (GlaxoSmithKline) and emerging therapies, such as Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Ustekinumab (Janssen Pharmaceutical), Atacicept (Merck), Dapirolizumab pegol (UCB Pharma/ Biogen), CC-220 (Celgene), IFNa KINOID (Neovacs), ILT-101 (Iltoo Pharma), BIIB059 (Biogen), Lulizumab (Bristol-MyersSquibb), Obexelimab (Xencor), KZR-616 (Kezar Life Sciences), Cenerimod (Idorsia Pharmaceuticals)), and others in the Systemic Lupus Erythematosus market by 2028.
Companies Mentioned
- GlaxoSmithKline
- AstraZeneca
- ImmuPharma
- Eli Lilly
- Janssen Pharmaceutical
- Merck
- UCB Pharma/ Biogen
- Celgene
- Neovacs
- Iltoo Pharma
- Biogen
- Bristol-MyersSquibb
- Xencor
- Kezar Life Science
- Idorsia Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ykzx13
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900